InMed’s Year-End Correspondence To Shareholders Focuses On Its Accomplishments And A Bullish Future Jan 6, 2022
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook Jan 5, 2022
InMed Pharmaceuticals Sees Historic Volume As It Enters Commercial Stage Of Bulk Cannabinoid Sales Nov 18, 2021
InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off” Sep 22, 2021
